Beijing Sinogenetic Biotechnology Co., Ltd. was established in 2021. Relying on the parent company's animal cloning and gene editing technology platform, the company has developed and constructed multi-species (dog/pig/cat/rabbit/mouse/rat) gene editing animal models, set up drug analysis and evaluation platforms such as pharmacological efficacy, pharmaco toxicology and safety evaluation platforms, and established multi-omics analysis, imaging electrophysiology and behavioral analysis platforms. It provides full-process preclinical CRO services on multi-breed gene editing model animal development and application for drug development and device evaluation, especially for innovative drug development such as gene therapy and cell therapy.